ADULT COVID-19 2025-2026

The Centers for Disease Control and Prevention (CDC) is seeking to award one or more Indefinite Delivery Indefinite Quantity (IDIQ) contracts for the purchase of all U.S-licensed or authorized COVID-19 brands with an adult indication. The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs and current and former U.S. Territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.